| Name | Title | Contact Details |
|---|
Zeltiq Aesthetics Inc is a Pleasanton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Occupational Health and Hygiene Corporation of America is a Lebanon, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Zutron Medical is a Kansas City, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioSig Technologies, Inc. (OTCQB: BSGM) is a medical device company that is developing a proprietary technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig`s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance for the PURE EP System.
At PRA Health Sciences, providing innovative solutions for our clients is what we do. Side by side with our clients, we strive to move drug discovery forward, helping develop life-saving and life-improving drugs. PRA has more than 10,000 employees working in 80+ countries providing comprehensive clinical development services across all phases. From full service clinical development to the pioneering Embedded Solutions model, PRA provides a broad spectrum of solutions that meet the demands of a diverse marketplace. As a top five CRO, we have worked on 100 plus marketed drugs across several therapeutic areas and conducted the pivotal or supportive trials that led to FDA and/or international regulatory approval of 50 plus such drugs.